Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (521-530 of 713) with videos related to

Pageof 72
Sort By:
Blood|May 31, 2012
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AMLBing Z Carter, Yihua Qiu, Xuelin Huang, et al.
Medcomm|April 29, 2026
BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβXiaocui Lu, Hui Fang, Yuan Liu, et al.
Frontiers in Oncology|September 14, 2013
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid LeukemiaAziz Nazha, Carlos Bueso-Ramos, Eli Estey, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2015
Characteristics of Sweet Syndrome in patients with acute myeloid leukemiaSyed M Kazmi, Naveen Pemmaraju, Keyur P Patel, et al.
The New England Journal of Medicine|September 17, 2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisSrdan Verstovsek, Hagop Kantarjian, Ruben A Mesa, et al.
Annals of Hematology|March 21, 2018
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemiaMaliha Khan, Tariq Muzzafar, Hagop Kantarjian, et al.
Cancer|August 28, 2003
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phaseSusan O'Brien, Francis Giles, Moshe Talpaz, et al.
Blood|January 10, 2012
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Clinical Lymphoma & Myeloma|December 16, 2005
T-cell prolymphocytic leukemia: a single-institution experienceFarhad Ravandi, Susan O'Brien, Dan Jones, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantationNaveen Pemmaraju, Maria Florencia Tanaka, Farhad Ravandi, et al.
Pageof 72

Showing results (521-530 of 713) with videos related to

Sort By:
Pageof 72
Blood|May 31, 2012
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AMLBing Z Carter, Yihua Qiu, Xuelin Huang, et al.
Medcomm|April 29, 2026
BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβXiaocui Lu, Hui Fang, Yuan Liu, et al.
Frontiers in Oncology|September 14, 2013
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid LeukemiaAziz Nazha, Carlos Bueso-Ramos, Eli Estey, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2015
Characteristics of Sweet Syndrome in patients with acute myeloid leukemiaSyed M Kazmi, Naveen Pemmaraju, Keyur P Patel, et al.
The New England Journal of Medicine|September 17, 2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisSrdan Verstovsek, Hagop Kantarjian, Ruben A Mesa, et al.
Annals of Hematology|March 21, 2018
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemiaMaliha Khan, Tariq Muzzafar, Hagop Kantarjian, et al.
Cancer|August 28, 2003
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phaseSusan O'Brien, Francis Giles, Moshe Talpaz, et al.
Blood|January 10, 2012
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Clinical Lymphoma & Myeloma|December 16, 2005
T-cell prolymphocytic leukemia: a single-institution experienceFarhad Ravandi, Susan O'Brien, Dan Jones, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantationNaveen Pemmaraju, Maria Florencia Tanaka, Farhad Ravandi, et al.
Pageof 72